FY2016 · ended Dec 31, 2016 · Revenue $0 · Filed Apr 2, 2018
Eledon Pharmaceuticals, Inc. (ELDN) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $88.8 million in cash and investments and $467,000 in total debt.
Revenue
$0
Net income
$-45.62M
-26.1% vs prior year
Operating cash flow (TTM)
$-73.86M
-14.5% vs year-ago TTM
Free cash flow
$-4.93M
EPS
$-0.52
+21.2% vs prior year
Dividend per share
None
Shares outstanding
75.85M
+26.7% vs prior year
Net cash
$88.29M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404281
- Former names
- Eledon Pharmaceuticals, Inc. (until Oct 30, 2026); Novus Therapeutics, Inc. (until Dec 22, 2020); Tokai Pharmaceuticals Inc (until May 4, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | — | — | -$43.0M | -$88.4M | -$36.9M |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M | -$34.5M |
| Diluted EPS | -$0.52 | -$0.66 | -$4.73 | -$6.16 | — |
| Operating cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | -$28.9M |
| Total assets | $169.0M | $177.4M | $89.1M | $92.8M | $170.5M |
| Total liabilities | $32.2M | $59.3M | $81.9M | $8.6M | $6.6M |
| Stockholders' equity | $81.1M | $62.4M | -$48.5M | $23.8M | $164.0M |
| Cash and investments | $133.3M | $140.2M | $51.1M | $56.4M | $84.8M |
| Total debt | $641,000 | $954,000 | $383,000 | $746,000 | $769,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 614 Eledon Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.